On June 5, 2023, immediately following the closing of the Private Placement, the Board of Directors of Telesis Bio, Inc. was increased from seven to eight directors and Paul Meister, a partner at Novalis LifeSciences LLC, was appointed as a director of the Company to fill the resulting vacancy.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3395 USD | -4.15% | +6.63% | -14.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.91% | 10.66M | |
+8.42% | 218B | |
+7.36% | 183B | |
+13.13% | 134B | |
+25.77% | 106B | |
-1.33% | 61.12B | |
+4.81% | 50.89B | |
+0.39% | 40.3B | |
+3.19% | 35.53B | |
+26.69% | 32.05B |
- Stock Market
- Equities
- TBIO Stock
- News Telesis Bio, Inc.
- Telesis Bio, Inc. Appoints Paul Meister as Director